Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NTLA vs RCUS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NTLA Captures Overall Composite Edge (50.7 HOLD vs 48.4 HOLD), While RCUS Leads 5–1 on Growth & Valuation Pillars

NTLA Overall Winner 6-Pillar Tally: NTLA 1 – 5 RCUS Matrix Metrics: NTLA 5 – 2 RCUS

As of Nov 16, 2026, Intellia Therapeutics, Inc (NTLA) captures the overall head-to-head institutional edge over Arcus Biosciences, Inc. (RCUS) on higher Unified Composite conviction (50.7/100 HOLD vs. 48.4/100 HOLD) after splitting the core matrix 5–2 (led by R&D & Supply-Chain Moat), while RCUS wins 5–1 across the 6-pillar growth and valuation breakdown. NTLA trades at $10.00 (N/M Forward P/E, -826.0% operating margin) versus RCUS at $16.97 (N/M Forward P/E, -475.0% operating margin).

  • Growth vs. Quality Trade-Off: NTLA earns the overall head-to-head edge with a stronger Unified Composite Score (50.7/100 HOLD vs. RCUS 48.4/100 HOLD) and 2.30β · 87% Vol risk profile, whereas RCUS leads top-line expansion (-65.4% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0); meanwhile RCUS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NTLA vs RCUS
NTLA NASDAQ Head-to-Head Winner
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$10.00
+3.09% 1D
Market Cap $1.5B
TTM Revenue $53M
Forward P/E N/M
Beta / 30D Vol 2.30β · 87% Vol
Unified Composite Score
50.7 / 100 HOLD
Tech 47.0 Fund 55.0 Flow 59.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.2%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $11.58 · SMA50: $11.86
RCUS NYSE
Arcus Biosciences, Inc.
Pharmaceutical Preparations
$16.97
-2.64% 1D
Market Cap $2.6B
TTM Revenue $100M
Forward P/E N/M
Beta / 30D Vol 1.56β · 90% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 48.0 Fund 59.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.6%), weak momentum, RSI 33
RSI-14: 33.3 · SMA20: $18.62 · SMA50: $22.36

6-Pillar Scorecard Institutional Category Breakdown (NTLA 1 – 5 RCUS)

Columns: Metric · NTLA · RCUS
1. Valuation Multiples RCUS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 29.1x 25.2x
2. Growth & Scale RCUS
Revenue Growth (YoY) -48.0% -65.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $53M $100M
Market Cap $1.5B $2.6B
3. Profitability & Quality RCUS
Gross Margin N/A N/A
Operating Margin -826.0% -475.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -62.6% -114.1%
4. Balance Sheet & Cash Flow RCUS
Cash Generation (TTM) -$358M -$466M
Cash Flow Margin N/A N/A
Net Cash / Leverage $74M Net Debt (0.38x D/E) $35M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RCUS
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 101.3% (78th %ile) 43.1% (1st %ile)
Put/Call OI Skew 0.42x (Call-Skewed) 0.08x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat NTLA
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NTLA (5) vs RCUS (2)
Institutional Metric NTLA RCUS Criterion Row Edge
Market Capitalization
Scale
$1.5B $2.6B Larger Scale RCUS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-48.0% -65.4% Higher Growth NTLA
Operating Margin (TTM)
Profitability
-826.0% -475.0% Higher Margin RCUS
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-62.6% -114.1% Higher ROE NTLA
52-Week Range Position
Momentum
20% ($8–$18) 1% ($17–$32) Stronger Trend NTLA
Beta / 30D Volatility
Risk Regime
2.30β · 87% Vol 1.56β · 90% Vol Lower Realized Risk NTLA
Unified Institutional Score
Composite Signal
50.7 / 100 (HOLD) 48.4 / 100 (HOLD) Higher Composite NTLA
Trailing 12M Revenue (USD)
Operating Scale
$53M $100M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 29.1x EV/Rev N/M PEG · 25.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$358M ($74M Net Debt (0.38x D/E)) -$466M ($35M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NTLA +10.85 pp
NTLA: -12.43% · RCUS: -23.28%
3M Horizon NTLA +28.7 pp
NTLA: -13.79% · RCUS: -42.49%
6M Horizon NTLA +6.28 pp
NTLA: -21.2% · RCUS: -27.48%
1Y Horizon NTLA +29.59 pp
NTLA: +15.34% · RCUS: -14.25%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NTLA Revenue RCUS Revenue NTLA Op. Margin RCUS Op. Margin Margin Leader
FY2018 $30M $10M -298.6% -656.8% NTLA
FY2019 $40M $10M -246.8% -591.4% NTLA
FY2020 $60M $80M -235.5% -159.0% RCUS
FY2021 $30M $380M -810.4% 14.1% RCUS
FY2022 $50M $40M -879.0% -736.8% RCUS
FY2023 $40M $40M -1420.5% -918.9% RCUS
FY2024 $60M $50M -923.1% -647.1% RCUS
FY2025 $70M $30M -651.7% -1169.7% NTLA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NTLA BREAKDOWN
94d in phase · OBV DISTRIBUTION
Current IV 101.3%
IV Percentile 78th %ile
Put/Call OI Skew 0.42x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NTLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RCUS BREAKDOWN
58d in phase · OBV NEUTRAL
Current IV 43.1%
IV Percentile 1st %ile
Put/Call OI Skew 0.08x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RCUS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NTLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.5B market capitalization and -826.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing
RCUS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.6B market capitalization and -475.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NTLA vs RCUS Key Questions & Quantitative Answers

As of Nov 16, 2026, Intellia Therapeutics, Inc (NTLA) captures the overall head-to-head institutional edge over Arcus Biosciences, Inc. (RCUS) on higher Unified Composite conviction (50.7/100 HOLD vs. 48.4/100 HOLD) after splitting the core matrix 5–2 (led by R&D & Supply-Chain Moat), while RCUS wins 5–1 across the 6-pillar growth and valuation breakdown. NTLA trades at $10.00 (N/M Forward P/E, -826.0% operating margin) versus RCUS at $16.97 (N/M Forward P/E, -475.0% operating margin). Growth vs. Quality Trade-Off: NTLA earns the overall head-to-head edge with a stronger Unified Composite Score (50.7/100 HOLD vs. RCUS 48.4/100 HOLD) and 2.30β · 87% Vol risk profile, whereas RCUS leads top-line expansion (-65.4% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0); meanwhile RCUS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RCUS leads the Growth & Scale pillar: NTLA posts -48.0% YoY revenue growth and +0.0% YoY earnings growth on $53M TTM revenue (N/A gross margin, -826.0% operating margin), compared with RCUS at -65.4% YoY revenue growth and +0.0% YoY earnings growth on $100M TTM revenue (N/A gross margin, -475.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NTLA cumulative revenue shifted +133.3% while RCUS shifted +200.0%. In operating R&D and SG&A reinvestment, NTLA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RCUS.

RCUS screens cheaper on headline valuation multiples. NTLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.1x EV/Revenue (unreported FCF margin), whereas RCUS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 25.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NTLA (-62.6% ROE) versus RCUS (-114.1% ROE) capital efficiency.

In options market volatility and institutional positioning, NTLA carries 101.3% implied volatility (78th %ile, Elevated (60th–80th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 87% Vol realized risk). By comparison, RCUS carries 43.1% implied volatility (1st %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.56β · 90% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.